EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer

Aryana Sepassi, Nico Gabriel, Sean D Sullivan, A Mark Fendrick, Jason A Zell, Dana B Mukamel

Value in Health · 2025

DOI: 10.1016/j.jval.2025.07.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Aryana Sepassi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA. …. Hauptthemen laut MEDLINE: Medicare Part D, Neoplasms, Health Expenditures, Inflation, Economic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To estimate changes in true out-of-pocket (TrOOP) spend from implementation of a $2000 cap for outpatient prescriptions as authorized by the 2022 Inflation Reduction Act (IRA) among Medicare Part D beneficiaries who received a diagnosis of cancer. METHODS: Medicare beneficiaries who received a diagnosis of cancer and at least one Part D claim for a prescription drug to treat cancer in 2021 were identified from a 5% random sample of beneficiaries. Part D drug expenditures were extracted and adjusted to 2025 expenditures using previously published methods. Total annual TrOOP spend per beneficiary was estimated under 2 scenarios: (1) 2025 Part D design expected without any IRA policies implemented and (2) IRA design with a $2000 TrOOP cap. We reported the proportion of beneficiaries who would experience TrOOP spend changes with the cap and estimated differences in TrOOP spend for these individuals. RESULTS: An estimated 42% of Part D beneficiaries with a diagnosis of cancer were predicted to have annual TrOOP spend of more than $2000 without the Part D cap. With the cap, these beneficiaries were expected to experience an average annual reduction of $8486 in TrOOP spend. Among these beneficiaries, with the TrOOP cap, those with hematologic cancers were expected to experience the greatest reduction ($10 846/beneficiary). CONCLUSIONS: Implementation of a Part D $2000 cap is expected to generate meaningful reduction in TrOOP spend for high-cost Medicare Part D beneficiaries who received a diagnosis of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medicare Part DNeoplasmsHealth ExpendituresInflation, EconomicFinancing, PersonalHumansUnited StatesMaleAgedFemaleAged, 80 and overPrescription Drugs

Stichwörter der Autor:innen

CancerInflation Reduction ActMedicare Part DOut-of-Pocket Drug ExpendituresTargeted Oral Anticancer Medication

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA. Electronic address: a1sepassi@health.ucsd.edu.
  • Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA.
  • The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, School of Pharmacy, Seattle, Washington, USA.
  • Department of Internal Medicine, Division of General Medicine, University of Michigan, School of Medicine, Ann Arbor, Michigan, USA.
  • Department of Medicine, University of California, Irvine School of Medicine, Irvine, California, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California, USA.
  • Department of Medicine, University of California, Irvine School of Medicine, Irvine, California, USA; iTEQC Research Program, University of California, Irvine, Irvine, California, USA.

Zitieren

APA

Sepassi, A., Gabriel, N., Sullivan, S. D., Fendrick, A. M., Zell, J. A., & Mukamel, D. B. (2025). Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer. Value in Health. https://doi.org/10.1016/j.jval.2025.07.003

Vancouver

Sepassi A, Gabriel N, Sullivan SD, Fendrick AM, Zell JA, Mukamel DB. Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer. Value in Health. 2025. doi:10.1016/j.jval.2025.07.003

BibTeX
@article{Sepassi2025,
  author = {Sepassi, Aryana and Gabriel, Nico and Sullivan, Sean D and Fendrick, A Mark and Zell, Jason A and Mukamel, Dana B},
  title = {Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer},
  journal = {Value in Health},
  year = {2025},
  doi = {10.1016/j.jval.2025.07.003}
}
Kostenlos starten →